APH1A (Anterior pharynx-defective 1A) is a critical subunit of the γ-secretase complex, a multiprotein enzyme essential for intramembrane proteolysis of various transmembrane substrates. This complex, composed of presenilin (PSEN1/2), nicastrin, PEN-2. and APH1A (or its homolog APH1B), plays a central role in Notch signaling activation and amyloid precursor protein (APP) processing. APH1A antibodies are widely used to study the expression, localization, and functional dynamics of this subunit in both physiological and pathological contexts. Researchers employ these antibodies in techniques like Western blot (WB), immunohistochemistry (IHC), and immunoprecipitation (Co-IP) to investigate γ-secretase assembly, substrate specificity, and regulatory mechanisms. Dysregulation of APH1A is implicated in Alzheimer’s disease (due to altered APP cleavage producing amyloid-β peptides) and cancers (via aberrant Notch signaling). Antibodies targeting APH1A help identify its interaction partners, assess isoform-specific contributions (e.g., APH1A vs. APH1B), and evaluate therapeutic interventions like γ-secretase inhibitors. Challenges include distinguishing APH1A from APH1B due to their high homology, necessitating antibody validation via knockout controls. Commercial APH1A antibodies are typically raised against unique epitopes in its C-terminal or loop regions. Their application advances understanding of γ-secretase-related diseases and supports drug development targeting this complex.